exhibit {num} 
emergent biosolutions awarded barda contract for advanced development and delivery of nuthrax , a next generation anthrax vaccine , valued at up to ${num} billion 
gaithersburg , md . , september {num} {num} —emergent biosolutions inc . ( nyse : ebs ) announced today that it has signed a multi-year contract with the biomedical advanced research and development authority ( barda ) , which is a division of the u . s . department of health and human services' office of the assistant secretary for preparedness and response , for the advanced development and delivery of nuthrax tm ( anthrax vaccine adsorbed with cpg {num} adjuvant ) , also known as av{num} the company's next generation anthrax vaccine candidate . the contract , valued at up to approximately ${num} billion , consists of a five-year base period of performance valued at approximately ${num} million to develop nuthrax for post-exposure prophylaxis of anthrax disease and to deliver to the strategic national stockpile ( sns ) an initial two million doses following emergency use authorization ( eua ) pre-approval by the u . s . food and drug administration ( fda ) . the company anticipates that fda could authorize nuthrax for emergency use as early as {num} triggering deliveries of nuthrax to the sns in {num} the contract also includes procurement options for the delivery of an additional {num} million to {num} million doses of nuthrax to the sns , valued from approximately ${num} million to up to ${num} billion , respectively , and options for an additional clinical study and post-marketing commitments valued at ${num} million , which if both were to be exercised in full , would increase the total contract value to up to ${num} billion . 
" emergent is pleased that barda has selected nuthrax to address the u . s . government's desire for a next generation anthrax vaccine with an enhanced product profile that includes requiring fewer doses and eliciting a faster immune response , " said daniel j . abdun-nabi , president and chief executive officer of emergent biosolutions . " we look forward to collaborating with barda to further develop nuthrax towards an eua-eligible product for the sns and subsequently towards fda licensure . " 
under the terms of the contract , activities to be completed under the base period of performance include licensure-enabling non-clinical and clinical studies , the manufacture and delivery of initial doses to the sns , and submission of a biologics license application to the fda with an expected fda-licensure under the animal rule . 
nuthrax is comprised of biothrax ® ( anthrax vaccine adsorbed ) in combination with the immunostimulatory oligodeoxynucleotide compound cpg {num} its safety , efficacy , and stability have been established through several phase 1 and phase 2 clinical studies . 
since {num} emergent has received five grants and contracts funded by barda and the national institute of allergy and infectious diseases totaling approximately ${num} million for the early stage and advanced development of nuthrax , including development of a dry formulation for the vaccine candidate . 
this contract hhso{num}c for the advanced development and delivery of nuthrax is funded by barda a division within the office of the assistant secretary for preparedness and response in the u . s . department of health and human services . 
about emergent biosolutions 
emergent biosolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life . we develop , manufacture , and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases . through our work , we envision protecting and enhancing {num} million lives with our products by {num} additional information about the company may be found at www . emergentbiosolutions . com . follow us @emergentbiosolu . 
safe harbor statement 
this press release includes forward-looking statements within the meaning of the private securities litigation reform act of {num} any statements , other than statements of historical fact , including statements regarding the total potential realizable value of the contract , the anticipated timing of eua eligibility , our strategy , future operations , prospects , plans and objectives with respect to nuthrax , and any other statements containing the words " believes , " " expects , " " anticipates , " " intends , " " plans , " " estimates " and similar expressions , are forward-looking statements . these forward-looking statements are based on our current intentions , beliefs and expectations regarding future events . we cannot guarantee that any forward-looking statement will be accurate . investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize , actual results could differ materially from our expectations . investors are , therefore , cautioned not to place undue reliance on any forward-looking statement . any forward-looking statement speaks only as of the date of this press release , and , except as required by law , we do not undertake to update any forward-looking statement to reflect new information , events or circumstances . 
there are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements , including appropriations for the development and procurement of nuthrax under the contract ; our ability to secure eua pre-authorization approval and licensure of nuthrax by fda within the anticipated timeframe , if at all ; barda's decisions to exercise options under the contract ; and our development and manufacturing capabilities and strategies . the foregoing sets forth many , but not all , of the factors that could cause actual results to differ from our expectations in any forward-looking statement . investors should consider this cautionary statement , as well as the risk factors identified in our periodic reports filed with the sec , when evaluating our forward-looking statements . 
## 
investor contact : media contact : 
robert g . burrows tracey schmitt lintott 
vice president , investor relations senior vice president , global public affairs 
{num}-{num}-{num} {num}-{num}-{num} 
burrowsr@ebsi . com schmittt@ebsi . com 
